COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance - 1st Edition - ISBN: 9780128213100, 9780128213117

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12

1st Edition

Editors: Andrew Freywald Franco Vizeacoumar
Hardcover ISBN: 9780128213100
eBook ISBN: 9780128213117
Imprint: Academic Press
Published Date: 17th November 2020
Page Count: 308
Sales tax will be calculated at check-out Price includes VAT/GST
280.86
155.00
135.00
175.00
148.75
Unavailable
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

1. Introductory Chapter
2. Tumor Metabolic Reprogramming in Therapeutic Resistance
3. Development of novel antiandrogens to overcome castrate resistant prostate cancer
4. Microenvironmental regulation of cancer response to therapy and therapy resistance
5. Revisiting immunogenic cell death to overcome treatment resistance in cancer immunotherapy
6. Preventing Phenotypic Plasticity in Cancer to Mitigate Therapy Resistance
7. Overcoming drug resistance in cancer with targeted radionuclide therapy
8. The PI3K pathway and chemotherapy resistance
9. Targeting leukemia stem cells in T-cell acute lymphoblastic leukemia
10. Escape from apoptosis: Anastasis as a potential mechanism of cancer drug resistance
11. From genetic data and structures to drug development: new approaches to targeting Eph receptors
12. Overcoming Therapeutic Resistance in Glioblastoma: a major clinical challenge


Description

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance.

Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges.

Key Features

  • Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field
  • Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients
  • Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies

Readership

Cancer researchers, medical scientists, clinicians, graduate students


Details

No. of pages:
308
Language:
English
Copyright:
© Academic Press 2020
Published:
17th November 2020
Imprint:
Academic Press
Hardcover ISBN:
9780128213100
eBook ISBN:
9780128213117

Ratings and Reviews


About the Editors

Andrew Freywald

Dr. Andrew Freywald, obtained his PhD in molecular and cell biology at the Weizmann Institute of Science, Israel, and completed his post-doctorate training in molecular immunology and cancer research at the Hospital for Sick Children, Toronto, Canada. His current research interests include cancer cell biology and tumor biology. He also serves as a scientific advisor for the biotech industry. The work of his research team at the College of Medicine, University of Saskatchewan focuses on investigating and targeting molecular mechanisms that determine tumor aggressiveness, and treatment resistance. His research program has been supported by several granting agencies, including CIHR, CCSRI, SHRF CRS, CFI, SCA, PCC, CBCF and TFRI, and also by the Be Like Bruce organization and the College of Medicine, University of Saskatchewan.

Affiliations and Expertise

College of Medicine, University of Saskatchewan, Canada

Franco Vizeacoumar

Dr. Franco J. Vizeacoumar, obtained his PhD in cell biology at the University of Alberta, Canada, and did his post-doctorate at the University of Toronto, Canada. His lab is working on developing genotype-directed cancer therapies for solid tumors by applying basic biological concepts called synthetic lethality and synthetic dosage lethality. The long term goal of his research group is to build a unified human genetic network that will capture genetic dependencies of cancer cells and define key therapeutic targets. The work in the Vizeacoumar lab has been supported by multiple granting agencies, such as CIHR, SCA, CRS, SHRF, CFI, TFRI, PCC, and also by the Be Like Bruce organization and the College of Medicine at the University of Saskatchewan.

Affiliations and Expertise

Saskatchewan Cancer Agency, College of Medicine, University of Saskatchewan, Canada